Matches in Wikidata for { <http://www.wikidata.org/entity/Q64150460> ?p ?o ?g. }
- Q64150460 description "clinical trial" @default.
- Q64150460 description "ensayu clínicu" @default.
- Q64150460 description "klinisch onderzoek" @default.
- Q64150460 description "клінічне випробування" @default.
- Q64150460 description "կլինիկական փորձարկում" @default.
- Q64150460 name "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer" @default.
- Q64150460 type Item @default.
- Q64150460 label "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer" @default.
- Q64150460 prefLabel "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer" @default.
- Q64150460 P1132 Q64150460-C1C1E01A-C5C2-41A8-8F71-4991963FC353 @default.
- Q64150460 P131 Q64150460-8BB6C362-E3CC-4531-9E4A-A99F40869FB3 @default.
- Q64150460 P1476 Q64150460-1574D1F7-6814-4CAA-9F30-3710A57C64F8 @default.
- Q64150460 P17 Q64150460-E5B6AE24-8094-4499-B081-BE137A9B6D00 @default.
- Q64150460 P2899 Q64150460-E5C3D30F-A069-4401-A898-EE33D5EF04CF @default.
- Q64150460 P3098 Q64150460-E2D783E9-6999-4951-BD4E-AABDD1E5F3C2 @default.
- Q64150460 P31 Q64150460-0EB852B9-9702-4B75-9BAE-7413317ADB32 @default.
- Q64150460 P4844 Q64150460-5368CB0F-257C-451D-8EC0-693B520C0E94 @default.
- Q64150460 P4844 Q64150460-817732E8-4900-4540-A052-26D4BD3B1335 @default.
- Q64150460 P4844 Q64150460-85EB4DAF-AAC1-4496-A92A-2FB30546205F @default.
- Q64150460 P580 Q64150460-156C1DA3-C581-4846-B6B7-0143AF9EEACC @default.
- Q64150460 P582 Q64150460-CE545850-A95A-4028-9B64-2F03F29F0760 @default.
- Q64150460 P6099 Q64150460-4AA84462-1567-40F0-BB3E-F1195C420110 @default.
- Q64150460 P6153 Q64150460-03090BD8-51E1-4055-9DAB-C11D90666984 @default.
- Q64150460 P6153 Q64150460-04203686-3C80-4371-9EA3-528EDF67B8D3 @default.
- Q64150460 P6153 Q64150460-07D63FA6-8B20-4B7D-B1D0-9BBE4C0830A2 @default.
- Q64150460 P6153 Q64150460-0B0B075B-EF27-46FB-A860-59C06DCC80C6 @default.
- Q64150460 P6153 Q64150460-0E8B45D7-4919-4375-9362-6D15FEB24FA0 @default.
- Q64150460 P6153 Q64150460-137FF53A-3CA1-4710-B23E-56E91309C96B @default.
- Q64150460 P6153 Q64150460-13A854AE-1A19-4E67-B32F-6AA5802909CA @default.
- Q64150460 P6153 Q64150460-155E6CBA-0565-49CC-B103-F243F04C83B6 @default.
- Q64150460 P6153 Q64150460-1CB7214E-F9F3-451F-9660-F56F09AF0B8D @default.
- Q64150460 P6153 Q64150460-1E58BECC-D154-4DF1-8693-9FCDCC6A4382 @default.
- Q64150460 P6153 Q64150460-1F63A5E4-A9FD-4606-BF46-2F0667C7F9BD @default.
- Q64150460 P6153 Q64150460-20ECC19D-AC69-4768-8D73-4900DBA20BF0 @default.
- Q64150460 P6153 Q64150460-24D2DBBC-33CA-4AE4-84CE-998BAB119B24 @default.
- Q64150460 P6153 Q64150460-269E3FB4-503C-4EEE-A23E-3E53AE3EE5E6 @default.
- Q64150460 P6153 Q64150460-2B8FA94C-AEB4-44F0-821E-054214A06E3F @default.
- Q64150460 P6153 Q64150460-2BCFE71D-F73C-447C-AC12-4D13096257D7 @default.
- Q64150460 P6153 Q64150460-336DBFEC-5753-444F-9F4E-B8488E19BBD2 @default.
- Q64150460 P6153 Q64150460-3549E52B-A444-4BC6-A3B1-C59B63A8403D @default.
- Q64150460 P6153 Q64150460-3A2718F2-F789-43F5-8460-EC51B0114AB4 @default.
- Q64150460 P6153 Q64150460-41182EE2-1316-462A-B5AB-809E0A180A42 @default.
- Q64150460 P6153 Q64150460-4123FCAA-C860-4D59-9A80-A0396A28DDCA @default.
- Q64150460 P6153 Q64150460-50A46D15-0740-4FE5-9C79-79E7611A21BB @default.
- Q64150460 P6153 Q64150460-579C2E03-4537-4FC3-9E90-61F8FE621AB3 @default.
- Q64150460 P6153 Q64150460-602F2B91-18AD-40A1-833B-5F8C1CE9DBD6 @default.
- Q64150460 P6153 Q64150460-67C7E1DB-B12D-4849-BA26-880E068B6DDC @default.
- Q64150460 P6153 Q64150460-6ABB1730-2256-47BE-B29E-B9B70B43BDB0 @default.
- Q64150460 P6153 Q64150460-6AE3D62A-3B28-4F45-9F7F-5C62E8AEFFF6 @default.
- Q64150460 P6153 Q64150460-6CE1C732-989B-4514-B704-E9A5675D1695 @default.
- Q64150460 P6153 Q64150460-6EFB58EA-C70A-4719-8A0C-622740300A76 @default.
- Q64150460 P6153 Q64150460-7ABF216D-3536-4E8D-B6B3-3E88052B1550 @default.
- Q64150460 P6153 Q64150460-7AFC2E91-E260-4563-868B-4357EA95C1D6 @default.
- Q64150460 P6153 Q64150460-8304B400-E168-4502-9AA6-C8C16C17612D @default.
- Q64150460 P6153 Q64150460-8883F20C-9F87-497B-A43D-11512B0DC99C @default.
- Q64150460 P6153 Q64150460-8AFB6A68-04B3-43A0-B052-AECEB772330D @default.
- Q64150460 P6153 Q64150460-93F6F7EF-B5C4-4C3F-AC4E-A890B42C5A08 @default.
- Q64150460 P6153 Q64150460-96E8E78D-9BE7-48D6-B7C6-5CF82D41682C @default.
- Q64150460 P6153 Q64150460-994ABF29-82FB-4394-8EB4-F63DA5E04F7A @default.
- Q64150460 P6153 Q64150460-A17194BD-68C6-4EA8-BB25-79B2562E0745 @default.
- Q64150460 P6153 Q64150460-ADDB8455-CC0E-4127-A1EE-9C42CBA84493 @default.
- Q64150460 P6153 Q64150460-C1969389-92D4-4C84-99F1-DDD498993984 @default.
- Q64150460 P6153 Q64150460-C3EE47A2-125A-4153-8D3A-182F438D8BE4 @default.
- Q64150460 P6153 Q64150460-C953E72F-BF14-428F-8888-0FDF6572EF2F @default.
- Q64150460 P6153 Q64150460-CED5D3B0-A17D-4F55-A2F4-6B66F127904D @default.
- Q64150460 P6153 Q64150460-DE4F94FA-9262-44CF-A7A8-11E25929A2B5 @default.
- Q64150460 P6153 Q64150460-E3F28DB2-15F3-44C0-AF77-2C352049DC6A @default.
- Q64150460 P6153 Q64150460-E87515C2-EC41-4C89-BE65-FB581E9BAA2A @default.
- Q64150460 P6153 Q64150460-E990A1D8-706D-4E41-8C5C-9D4AF074FBD5 @default.
- Q64150460 P6153 Q64150460-EC367758-2633-48C1-8D38-7476E4E6DDEB @default.
- Q64150460 P6153 Q64150460-F1F949C2-806E-4E1D-BA66-BF8505D98AF4 @default.
- Q64150460 P6153 Q64150460-F6CB7BE6-A889-4123-8091-75B7C784C604 @default.
- Q64150460 P8363 Q64150460-25F1C6C1-5F2A-4C6A-A0F6-4CCF4AB4B9B4 @default.
- Q64150460 P1132 "+312" @default.
- Q64150460 P131 Q1183 @default.
- Q64150460 P1476 "A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation" @default.
- Q64150460 P17 Q30 @default.
- Q64150460 P2899 "+18" @default.
- Q64150460 P3098 "NCT02003209" @default.
- Q64150460 P31 Q30612 @default.
- Q64150460 P4844 Q1998021 @default.
- Q64150460 P4844 Q415588 @default.
- Q64150460 P4844 Q50429626 @default.
- Q64150460 P580 "2014-01-15T00:00:00Z" @default.
- Q64150460 P582 "2021-08-31T00:00:00Z" @default.
- Q64150460 P6099 Q42824827 @default.
- Q64150460 P6153 Q1052562 @default.
- Q64150460 P6153 Q1057447 @default.
- Q64150460 P6153 Q115376 @default.
- Q64150460 P6153 Q14716149 @default.
- Q64150460 P6153 Q192334 @default.
- Q64150460 P6153 Q22033932 @default.
- Q64150460 P6153 Q2302319 @default.
- Q64150460 P6153 Q230492 @default.
- Q64150460 P6153 Q235034 @default.
- Q64150460 P6153 Q2725999 @default.
- Q64150460 P6153 Q28924596 @default.
- Q64150460 P6153 Q30253539 @default.
- Q64150460 P6153 Q30258334 @default.
- Q64150460 P6153 Q30269404 @default.